News

Net profit of Dr Lal Pathlabs declined 15.18% to Rs 131.30 crore in the quarter ended March 2026 as against Rs 154.80 crore during the previous quarter ended March 2025. Sales rose 16.61% to Rs 702.70 crore in the quarter ended March 2026 as against Rs 602.60 crore during the previous quarter ended March 2025.For the full year,net profit rose 3.63% to Rs 504.80 crore in the year ended March 2026 as against Rs 487.10 crore during the previous year ended March 2025. Sales rose 12.25% to Rs 2762.90 crore in the year ended March 2026 as against Rs 2461.40 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales702.70602.60 17 2762.902461.40 12 OPM %26.5828.05 -28.3228.26 - PBDT204.70189.80 8 861.00766.60 12 PBT160.10153.40 4 699.20624.70 12 NP131.30154.80 -15 504.80487.10 4 Powered by Capital Market - Live News

The board of Dr Lal Pathlabs at its meeting held on 30 April 2026 has approved the incorporation of wholly owned subsidiary company in Dubai in the name and style of Dr Lal Pathlabs FZCO.

The board of Dr Lal Pathlabs at its meeting held on 30 April 2026 has approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre (SDCPL) from its existing Shareholders. Post acquisition, SDCPL shall become a wholly owned subsidiary of the company.

Dr. Lal PathLabs announced that the 32th Annual General Meeting(AGM) of the company will be held on 25 July 2026.

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 30 April 2026, has recommended a Final Dividend of Rs.4 per share (i.e.40%), subject to the approval of the shareholders.